Energy And Related Services Tenders

Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

Testing System Primary and Secondary Technology for Apg Switchgear

Dps for Marketing, Communications and Media Planning

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Erythropoietin (Atc Code: B03xa01).

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Open House Contracts for Multiple Active Ingredients/Active Ingredient Combinations

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Substance Rivaroxaban (Xarelto(R)) - Hkk

Implementation and Implementation of a Dynamic System for the Acquisition of Supplies for Current Use, Products Available in the Market and Whose General Characteristics are Adapted to the Needs Of...

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Nadroparin (Atc Code: B01ab06).